Eleonora Sosa Cuevas
7PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jan 27, 2025
MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma.Camille Niveau, Mélanie Cettour-Cave, Stéphane Mouret
|May 14, 2024
Glycans in melanoma: Drivers of tumour progression but sweet targets to exploit for immunotherapy.Camille Niveau, Eleonora Sosa Cuevas, Philippe Saas
|May 16, 2023
Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation.Eleonora Sosa Cuevas, Philippe Saas, Caroline Aspord
|May 06, 2022
Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1-)-pDC subset negatively correlated with clinical outcomes in melanoma patients.Eleonora Sosa Cuevas, Nathalie Bendriss-Vermare, Stephane Mouret
|Nov 17, 2021
Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes.Pauline Girard, Eleonora Sosa Cuevas, Benedicte Ponsard
|Dec 14, 2020
Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs.Laurissa Ouaguia, Tania Dufeu-Duchesne, Vincent Leroy
Pageof 2
